Drug manufacturer Amgen is providing refunds for overcharges during varying periods over three years on some of its top selling drugs including Enbrel ($4.8 billion in U.S. sales in 2020), Neulasta ($2 billion), Kyprolis ($710 million), Aranesp ($629 million), Epogen
…
America’s oldest consumer protection group, shunned by some former allies in the labor movement for alleged favoritism toward its corporate donor Amazon, has slammed the 340B program in a commentary for the conservative-leaning news and opinion website RealClearHealth.
“Sadly, as
…
Drug manufacturer AstraZeneca effective June 1 will stop offering voluntary 340B pricing on its orphan drugs to critical access hospitals, sole community hospitals, rural referral centers, and free-standing cancer hospitals, the company said yesterday.
“AstraZeneca is making this change to
…
Drug manufacturer Merck today extended its restrictions on 340B pricing involving contract pharmacies to community health centers. The restrictions have applied only to hospital covered entities until now.
Other grantee covered entities remain exempt “at this time,” Merck said, adding
…
340B Report, an independent news organization covering the 340B drug pricing program, is holding its first event—a May 18 webinar about implementing drug manufacturers’ controversial new rules on 340B contract pharmacies. It is an exclusive and free
…
Drug manufacturer Sanofi drew attention this month when it added 45-day time limits for replenishment orders and claims submissions to its conditions on 340B pricing when covered entities use contract pharmacies.
Pfizer and Amgen also recently added similar 45-day lookback requirements
…
Ryan White Clinics for 340B Access (RWC-340B) has asked drug manufacturer Gilead to exempt all Ryan White clinics from the company’s conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies.
RWC-340B made the
…
UPDATE Thursday, April 21, 2022, 5:00 p.m. EDT—AbbVie issued this statement: AbbVie supports the 340B program and is committed to the program’s goal of improving access to medicines for uninsured and vulnerable patients. Our 340B initiative does not block access
…
Drug manufacturer Sanofi has made two major changes to its conditions on 340B pricing when health centers and certain hospitals and use contract pharmacies, a company spokesperson confirms. One is raising flags among 340B providers and the other appears to
…*Sign up for news summaries and alerts from 340B Report